Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for Platysma Prominence
NCT04994535Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2021
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of botulinum toxin type A in platysma prominence, sponsored by AbbVie Inc.. Started Aug 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
platysma prominence
Beyond the preview
Go deeper on NCT04994535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994535.